• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Novartis - Articles and news items

globe-pill

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

breast-cancer-pills

FDA grants priority review for Novartis’ first-line treatment of HR+/HER2- advanced breast cancer

Industry news / 7 November 2016 / Niamh Louise Marriott, Digital Content Producer

The US Food and Drug Administration (FDA) accepted Novartis’ new drug application (NDA) for filing and granted priority review for LEE011 (ribociclib)…

novartis-award

Novartis wins “Discovery of the Decade” and “Best Biotechnology Product” awards

Industry news / 31 October 2016 / Niamh Louise Marriott, Digital Content Producer

Novartis has been awarded the 2016 Prix Galien USA Award “Discovery of the Decade” Award for Best Pharmaceutical Product for the drug Gleevec, as well as…

novartis-melanoma-3-years

Patient overall survival still strong three years after Novartis’ melanoma trial

Industry news / 12 October 2016 / Niamh Louise Marriott, Digital Content Producer

45% of patients receiving the combination of Tafinlar + Mekinist (95% CI, 39.1%-49.8%) compared with 31% of patients who received vemurafenib monotherapy…

novartis-breast-cancer

Novartis’ HR+/HER2- advanced breast cancer trial gives superior progression-free survival

Industry news / 10 October 2016 / Niamh Louise Marriott, Digital Content Producer

The results demonstrate that LEE011 plus letrozole reduced the risk of death or progression by 44%. The combination significantly improved PFS across…

novartiscover

Novartis’ plaque psoriasis drug keeps skin clear 4 years post treatment

Industry news / 4 October 2016 / Niamh Louise Marriott, Digital Content Producer

The aim of Novartis’ plaque psoriasis treatment is clear skin and was achieved by 68.5% of patients at Year 1 and this high rate was maintained to Year 4…

psoriasis-hands

Novartis’ global study shows 57% of psoriasis patients didn’t reach clear skin treatment goal

Industry news / 3 October 2016 / Niamh Louise Marriott, Digital Content Producer

People with the autoimmune disease, psoriasis, also report that they face discrimination, humiliation, and mental illness…

ankylosing-spondylitis

NICE recommends Novartis’ ankylosing spondylitis drug

Industry news / 29 September 2016 / Niamh Louise Marriott, Digital Content Producer

NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy…

expanded-novartis

Expanded use for Novartis’ Periodic Fever Syndrome drug after 3 new FDA approvals

Industry news / 27 September 2016 / Niamh Louise Marriott, Digital Content Producer

The expanded use is for Ilaris, a selective, high-affinity, human monoclonal antibody that inhibits Interleukin-1 (IL-1) beta, part of the immune system…

progression-ms

Novartis’ long term RRMS drug limits disease progression

Industry news / 16 September 2016 / Niamh Louise Marriott, Digital Content Producer

Gilenya impacts four key measures of disease activity: relapses, MRI lesions, brain shrinkage (brain volume loss) and disability progression…

biosimilar-disease-drug

FDA approves Novartis’ biosimilar to treat multiple inflammatory diseases

Industry news / 1 September 2016 / Niamh Louise Marriott, Digital Content Producer

The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis…

ofatumumab-genmab

FDA approves Genmab’s ofatumumab for relapsed CLL

Industry news / 31 August 2016 / Niamh Louise Marriott, Digital Content Producer

Approval is supported by the Phase III complement study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +